On October 3, Shimadzu Corporation released the Nexera CL LCMS system in Japan. The system is designed for clinical applications, such as analyzing target components in blood, urine, or other biological samples. It consists of a separation unit and a detection unit. The separation unit is a liquid chromatograph (LC) that separates target substances based on their chemical characteristics. The detection unit is either a mass spectrometer that separates and detects substances by mass or a UV detector that detects them by light absorption.
This product has been notified in Japan as a Class I medical device under the Pharmaceuticals and Medical Devices Act (PMD Act), which ensures the quality, efficacy, and safety of pharmaceuticals and medical devices.
Nexera CL LCMS System
Liquid chromatograph mass spectrometer (LC-MS) systems are used for R&D and quality control applications in a wide range of fields, such as pharmaceuticals, chemicals, foods, and environmental testing. Due to instrument advancements in recent years, the scope of clinical applications has been expanding, such as neonatal mass screening and therapeutic drug monitoring in blood. Compared to immunoassay methods, LC-MS analysis generally allows simultaneous measurement of more components, offers comparable sensitivity, and achieves higher precision by avoiding cross-reactions between different antibodies. Consequently, LC-MS systems are now used in the clinical field.
Therefore, in 2015, Shimadzu released the Nexera LC-MS/MS and Prominence LC-MS/MS systems (Class I medical devices) for clinical applications in Japan. Similarly, Shimadzu has also been releasing LC and LC-MS products in the United States and Europe. The new Nexera CL LCMS system features a state-of-the-art separation unit and an expanded line of UV detector options, some of which can be added as optional units. This system has been released to satisfy a broader range of customer needs.